Achieved Q4 2024 GAAP Net Income of $3.6 million Generated full-year 2024 Net Revenue of $144.2 million , up 14% year-over-year Delivered full-year 2024 adjusted EBITDA of $8.6 million Generated ZYNRELEF ® Q4 2024 Net Revenue of $8.5 million and launched the ZYNRELEF Vial Access Needle ("VAN") in December 2024 U.S. District Court ruled in favor of Heron in patent lawsuit against Fresenius Kabi USA , LLC, and upheld the... Read More

CARY, N.C. , Feb. 13, 2025 /PRNewswire/ -- Heron Therapeutics, Inc . (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 27, 2025 , at 8:00 a.m. ET to report fourth quarter and full year 2024 financial results and discuss recent business highlights. The conference call can be accessed by phone... Read More

SAN DIEGO , Dec. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of the Company's headquarters from San Diego, California to Cary, North Carolina , effective January 1, 2025 . A majority of Heron's Management Team and corporate employees work from the Cary office, which is near the Research Triangle Park... Read More

Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA , LLC SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware ruled in Heron's favor in the Company's patent litigation against Fresenius Kabi USA , LLC with respect to CINVANTI®... Read More

Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN") approved in September and on track for Q4 2024 launch CMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment in both the hospital outpatient... Read More

SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Mr. Kaseta currently serves as... Read More

SAN DIEGO , Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024 , at 8:00 a.m. ET to report third quarter 2024 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the... Read More

SAN DIEGO , Oct. 10, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's ability to supply CINVANTI ® (aprepitant) injectable emulsion and SUSTOL ® (granisetron) extended-release injection for Chemotherapy Induced Nausea and Vomiting ("CINV") prevention and APONVIE ® for Postoperative Nausea and Vomiting ("PONV")... Read More

The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time The VAN is expected to launch in Q4 2024 SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval... Read More

SAN DIEGO , Sept. 3, 2024 /PRNewswire/ - - Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business... Read More

Second quarter Net Product Sales of $36.0 million , which increased from $31.8 million for the same period in 2023 ZYNRELEF ® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act") SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology... Read More

SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, August 6, 2024 , at 4:30 p.m. ET to report second quarter 2024 financial results and discuss recent business highlights. The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871... Read More

SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF® (bupivacaine and meloxicam) is included in the proposed 2025 Non-Opioid Policy for Pain Relief under the Medicare hospital Outpatient Prospective Payment System ("OPPS") and the Medicare Ambulatory Surgical Center ("ASC") payment system (the... Read More

The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 SAN DIEGO , July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF ® (bupivacaine... Read More

SAN DIEGO , May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc . (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement ("PAS") submission to the U.S. Food and Drug Administration ("FDA") for ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN"). Heron expects to receive the assigned action date for completion... Read More

Net Product Sales of $34.7 million , which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02) , which decreased from $(0.27) for the same period in 2023. Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF ® promotional efforts in the first quarter of 2024. Gross Margin improved to 76% for the quarter, up from 43% for the same period last year. FDA approval of expanded... Read More

SAN DIEGO , April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024 , at 8:30 a.m. ET to report first quarter 2024 financial results and discuss recent business highlights. The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871... Read More

SAN DIEGO , April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET . The event will include presentations from members of the Company's leadership team highlighting the renewed focus across the Acute Care and Oncology franchises and panel discussions... Read More

SAN DIEGO , March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard , Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024 , at 11:00 AM ET at the 23 rd Annual Needham Virtual Healthcare Conference. The conference is being held in a virtual format, April 8-11, 2024. A live webcast of the... Read More

2023 oncology care franchise revenue was $107.9 million , exceeding full-year 2023 guidance ZYNRELEF ® achieved quarterly record of $5.6 million in Q4 Net Product Sales Ended 2023 with cash and cash equivalents of $80.4 million Announced partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF promotional efforts on January 7, 2024 Received FDA approval for expanded indication of ZYNRELEF on January 23, 2024 SAN... Read More

SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, March 12, 2024 , at 4:30 p.m. ET to report fourth quarter and full year 2023 financial results and discuss recent business highlights. The conference call can be accessed by dialing (646) 307-1963 in the U.S. or... Read More

Expanded indication for ZYNRELEF now covers approximately 13 million procedures annually SAN DIEGO , Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution to expand the... Read More

SAN DIEGO , Jan. 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it has entered into a five-year distributor partnership with CrossLink Life Sciences, LLC to expand the sales network supporting ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution. The partnership will launch in several phases, initially at a regional level, followed... Read More

Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 million to $106 million from a prior range of $99 million to $103 million We anticipate full-year 2023 Net Product Sales to be in the range of $123 million to $125 million and full-year 2024 Net Product Sales to be in the range of $138 million to $158 million Full-year 2024 EBITDA (excluding stock compensation)... Read More

SAN DIEGO , Nov. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the company will host a conference call and live webcast on Tuesday, November 14, 2023 at 4:30 p.m. ET to report third quarter 2023 financial results and... Read More

Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equity raise Favorable outcome at Markman hearing in pending CINVANTI ® ANDA patent litigation New management team in place Reiterating full-year net product sales guidance for the oncology care franchise of $99 - $103 million SAN DIEGO , Aug. 14, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron"... Read More

SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the company will host a conference call and live webcast on Monday, August 14, 2023 at 4:30 p.m. ET to report second quarter 2023 financial results and... Read More

Expected overall cash savings of $75 million through 2025 New executive management team in place SAN DIEGO , July 24, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced a cost reduction plan and a corporate restructuring, following... Read More

SAN DIEGO , July 24, 2023 /PRNewswire/ -- Heron Therapeutics, Inc . (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, announced today that it has entered into a securities purchase agreement to sell in a private placement to institutional investors, led by existing investor Rubric Capital... Read More

SAN DIEGO , June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Ira Duarte as Chief Financial Officer. Ms. Duarte has more than twenty-five years of experience in a variety of finance and... Read More

SAN DIEGO , June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of William Forbes , Pharm.D., as Executive Vice President, Chief Development Officer. In addition, Kimberly Manhard , Heron's... Read More

Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million , Compared to First Quarter Net Product Sales in 2022 Appointment of Craig Collard as Chief Executive Officer (CEO) and Jason Grillot as Vice President (VP), Sales and Marketing, of the Acute Care Franchise. SAN DIEGO , May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on... Read More

SAN DIEGO , May 4, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report first quarter 2023 financial... Read More

SAN DIEGO , April 20, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced changes to its commercial leadership team, including the appointment of Jason Grillot as Vice President, Sales and Marketing, Acute Care, effective... Read More

SAN DIEGO , April 17, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Craig Collard , Chief Executive Officer of Heron, will participate in a fireside chat on Thursday, April 20, 2023 , at 11:45 AM ET at the 22... Read More

Craig Collard Appointed CEO Adam Morgan Named Chairman of the Board SAN DIEGO , April 3, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the appointment of Craig Collard as Chief Executive Officer... Read More

Annual Net Product Sales Across the Company Grew 25% to $107.7 million in 2022, Compared to Annual Net Product Sales in 2021 APONVIE ™ Commercially Launched on March 6, 2023 ZYNRELEF ® Net Product Sales for Fourth Quarter of 2022 Increased 44% Over Prior Quarter to $3.9 Million Oncology Care Franchise Net Product Sales for 2022 Grew 17% Over Prior Year to $97.5 Million SAN DIEGO , March 23, 2023 /PRNewswire/ -- Heron... Read More

SAN DIEGO , March 13, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that CMS has approved transitional pass-through status for APONVIE (aprepitant) injectable emulsion, which will be established for three years... Read More

SAN DIEGO , March 10, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Thursday, March 23, 2023 at 4:30 p.m. ET to report fourth quarter and full year... Read More

APONVIE, the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK 1 ) receptor antagonist indicated for Postoperative Nausea and Vomiting (PONV) APONVIE is delivered via a single IV push and offers 48 hours of PONV prevention Leveraging existing acute care commercial teams across the U.S. SAN DIEGO , March 6, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage... Read More

SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that company management will participate in a fireside chat on Tuesday, March 7, 2023 at 2:10 PM ET at the 43 rd Annual Cowen Healthcare... Read More

Appoints Three New Independent Directors SAN DIEGO , Feb. 22, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that it has entered into a cooperation agreement with two of its shareholders, Rubric... Read More

Preliminary Annual Net Product Sales Across the Company Grew 24% to $106.7 Million in 2022, Compared to Annual Net Product Sales in 2021 Preliminary Fourth-Quarter 2022 Net Product Sales for ZYNRELEF ® Increased 40% to Approximately $3.8 Million Preliminary Full-Year 2022 Net Product Sales for Oncology Care Franchise of Approximately $96.6 Million , Versus Guidance of $93 Million to $95 Million Full-Year 2023 Net Product... Read More

Supplemental New Drug Application Submitted Requesting Expansion of Indication to Broadly Cover Soft Tissue and Orthopedic Surgical Procedures Omnibus Spending Bill (H.R. 2617) Includes Provision to Provide Separate Payments for Non-Opioid Treatment for Pain Relief in the Outpatient Setting Beginning January 1, 2025 SAN DIEGO , Dec. 29, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage... Read More

SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that company management will participate in a fireside chat on Thursday, December 1, 2022 at 10:05 AM ET at the Evercore ISI 5 th Annual HealthCONX... Read More